OSI-774 (Erlotinib, Tarceva) in Elderly Patients
The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.
Checked against the public recordLast updated Dec 30, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Montefiore Medical Center
- Interventions being studied
- Drug: Tarceva
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients must have confirmed non-small cell lung cancer. Age \> 65 years Patients must have adequate organ and marrow function Exclusion Criteria: * Patients who have had prior chemotherapy will be excluded. Patients may not be receiving any other investigational agents.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Beth Israel Medical CenterNew York, New York
- New York UniversityNew York, New York
- Albert Einstein Cancer CenterThe Bronx, New York
- Montefiore Medical Center-The Bronx, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 30, 2019. Always confirm current availability with the study team.